The Look AHEAD Study: A description of the lifestyle intervention and the evidence supporting it

被引:1
作者
Wadden, Thomas A.
West, Delia Smith
Delahanty, Linda M.
Jakicic, John M.
Rejeski, W. Jack
Berkowitz, Robert I.
Williamson, Donald A.
Kelley, David E.
Kumanyika, Shiriki K.
Hill, James O.
Tomchee, Christine M.
Armstrong, Nell
Bantle, John
Bolin, Paula
Cerniauskas, Barbara
Foreyt, John
Gregg, Edward
Kuczmarski, Robert
Miller, Marsha
Mobley, Connie
Obarzanek, Eva
Otto, Amy
Pal, Carmen
Reeves, Rebecca
Vitolins, Mara
Wing, Rena
Yanovski, Susan
机构
[1] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[2] Pennington Biomed Res Ctr, Baton Rouge, LA USA
[3] Massachusetts Gen Hosp, Boston Harvard Ctr, Boston, MA 02114 USA
[4] Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Univ Pittsburgh, Pittsburgh, PA 15260 USA
[7] Brown Univ, Providence, RI 02912 USA
关键词
weight loss; diet; physical activity; lifestyle modification; weight maintenance;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Look AHEAD (Action for Health in Diabetes) study is a multicenter, randomized controlled trial designed to determine whether intentional weight loss reduces cardiovascular morbidity and mortality in overweight individuals with type 2 diabetes. The study began in 2001 and is scheduled to conclude in 2012. A total of 5145 participants have been randomly assigned to a lifestyle intervention or to an enhanced usual care condition (i.e., diabetes support and education). This article describes the lifestyle intervention and the empirical evidence to support it. The two principal intervention goals are to induce a mean loss >= 7% of initial weight and to increase participants' moderately intense physical activity to >= 175 min/wk. For the first 6 months, participants attend one individual and three group sessions per month and are encouraged to replace two meals and one snack a day with liquid shakes and meal bars. From months 7 to 12, they attend one individual and two group meetings per month and continue to replace one meal per day (which is recommended for the study's duration). Starting at month 7, more intensive behavioral interventions and weight loss medication are available from a toolbox, designed to help participants with limited weight loss. In Years 2 to 4, treatment is provided mainly on an individual basis and includes at least one on-site visit per month and a second contact by telephone, mail, or e-mail. After Year 4, participants are offered monthly individual visits. The intervention is delivered by a multidisciplinary team that includes medical staff who monitor participants at risk of hypoglycemic episodes.
引用
收藏
页码:737 / 752
页数:16
相关论文
共 87 条
  • [1] Effects of lifestyle activity vs structured aerobic exercise in obese women - A randomized trial
    Andersen, RE
    Wadden, TA
    Bartlett, SJ
    Zemel, B
    Verde, TJ
    Franckowiak, SC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (04): : 335 - 340
  • [2] The efficacy and safety of sibutramine for weight loss - A systematic review
    Arterburn, DE
    Crane, PK
    Veenstra, DL
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) : 994 - 1003
  • [3] Weight control during the holidays: Highly consistent self-monitoring as a potentially useful coping mechanism
    Baker, RC
    Kirschenbaum, DS
    [J]. HEALTH PSYCHOLOGY, 1998, 17 (04) : 367 - 370
  • [4] Bell EA, 2001, AM J CLIN NUTR, V73, P1010
  • [5] Behavior therapy and sibutramine for the treatment of adolescent obesity - A randomized controlled trial
    Berkowitz, RI
    Wadden, TA
    Tershakovec, AM
    Cronquist, JL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14): : 1805 - 1812
  • [6] Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes
    Brancati, F
    Charleston, J
    Cheskin, L
    Clark, J
    DiGregorio-Celnik, D
    Friedman-Donze, L
    Rubin, R
    Stewart, K
    Bray, GA
    DeLee, DG
    Boss, KR
    Greenway, FL
    Lovejoy, JC
    Ryan, DH
    Williamson, DA
    West, DS
    DiLillo, V
    Raczynski, JM
    Lewis, CE
    Oberman, A
    Thomas, S
    Nathan, DM
    Horton, ES
    Turgeon, H
    Jackson, SD
    Blackburn, GL
    Delahanty, L
    Steiner, B
    Cagliero, E
    Mantzoros, C
    Hill, JO
    Phillipp, J
    Hamman, RF
    Schwartz, R
    Regensteiner, J
    Van Dorsten, B
    McDermott, MT
    Dills, DG
    Foreyt, JP
    Reeves, RS
    Pownell, HJ
    Balasubramanyam, A
    Jones, PH
    Saad, MF
    Jinagouda, S
    Chiu, K
    Morales, L
    Ghazarian, S
    Navarrete, G
    Iqbal, N
    [J]. CONTROLLED CLINICAL TRIALS, 2003, 24 (05): : 610 - 628
  • [7] Sibutramine produces dose-related weight loss
    Bray, GA
    Blackburn, GL
    Ferguson, JM
    Greenway, FL
    Jain, AK
    Mendel, CM
    Mendels, J
    Ryan, DH
    Schwartz, SL
    Scheinbaum, ML
    Seaton, TB
    [J]. OBESITY RESEARCH, 1999, 7 (02): : 189 - 198
  • [8] Bariatric surgery: A systematic review and meta-analysis
    Buchwald, H
    Avidor, Y
    Braunwald, E
    Jensen, MD
    Pories, W
    Fahrbach, K
    Schoelles, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (14): : 1724 - 1737
  • [9] EFFECTS OF WEIGHT-REDUCTION ON BLOOD-LIPIDS AND LIPOPROTEINS - A METAANALYSIS
    DATTILO, AM
    KRISETHERTON, PM
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1992, 56 (02) : 320 - 328
  • [10] Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial
    Davidson, MH
    Hauptman, J
    DiGirolamo, M
    Foreyt, JP
    Halsted, CH
    Heber, D
    Heimburger, DC
    Lucas, CP
    Robbins, DC
    Chung, J
    Heymsfield, SB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03): : 235 - 242